Skip to main content

Weber William John's Form 4 filing

Calidi Biotherapeutics, Inc. (CLDI) · filed Sep 14, 2023

Accession no.
0000899243-23-019095
Filed
Sep 14, 2023, 9:00 PM ET
Trade date
Jun 16-Sep 12, 2023
Filing delay
90 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 5 derivative transactions. It was filed 90 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Weber William JohnCIK 000146464810% Owner
First Light Acquisition Group, LLCCIK 000185548910% Owner
FLAG Sponsor Manager, LLCCIK 000188292010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 12, 2023Common Stock, par value $0.0001 per shareCConversionAcquired+1,931,852––1,931,852Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 16, 2023Class A Common Stock, par value $0.0001 per shareSSaleDisposed−191,990––2,383,813Indirect
Sep 12, 2023Class A Common Stock, par value $0.0001 per shareSSaleDisposed−99,388––2,284,425Indirect
Sep 12, 2023Class A Common Stock, par value $0.0001 per shareSSaleDisposed−186,372––2,098,053Indirect
Sep 12, 2023Class A Common Stock, par value $0.0001 per shareJOtherDisposed−166,201––1,931,852Indirect
Sep 12, 2023Class A Common Stock, par value $0.0001 per shareCConversionDisposed−1,931,852––0Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)